177Lu-PSMA for advanced prostate cancer: are we ready to play big?
C Hehakaya, EHM Moors, HM Verkooijen… - European Journal of …, 2021 - Springer
Prostate cancer is the second most common cancer among men [1, 2]. Although patients
with localized prostate cancer receive treatment with curative intent, a significant proportion …
with localized prostate cancer receive treatment with curative intent, a significant proportion …
Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks
Abstract Purpose [177 Lu] Lu-PSMA-617 radio-ligand therapy (PSMA-RLT) is emerging in
patients with an advanced metastatic castration-resistant prostate cancer (mCRPC). Here …
patients with an advanced metastatic castration-resistant prostate cancer (mCRPC). Here …
VISION: An international, prospective, open-label, multicenter, randomized phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA …
TPS5099 Background: The novel therapeutic drug 177Lu-PSMA-617 is a prostate specific
membrane antigen (PSMA) targeting agent to deliver radionuclide therapy for the treatment …
membrane antigen (PSMA) targeting agent to deliver radionuclide therapy for the treatment …
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Background Progressive metastatic castration-resistant prostate cancer is a highly lethal
disorder and new effective therapeutic agents that improve patient outcomes are urgently …
disorder and new effective therapeutic agents that improve patient outcomes are urgently …
[引用][C] Short-course 177Lu-PSMA-617 Radioligand Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer: Time to Take the Leap?
Short-course 177Lu-PSMA-617 Radioligand Therapy in High-volume Metastatic Hormone-sensitive
Prostate Cancer: Time to Take the Leap? - Abstract - Europe PMC Sign in | Create an …
Prostate Cancer: Time to Take the Leap? - Abstract - Europe PMC Sign in | Create an …
First experience with 177Lu-PSMA-617 therapy for advanced prostate cancer in the Netherlands
L van Kalmthout, A Braat, M Lam… - Clinical nuclear …, 2019 - journals.lww.com
Purpose The present study summarizes the first experience with 177 Lu-PSMA-617 (177 Lu-
PSMA) treatment in metastatic castration-resistant prostate cancer (PCa) in our institution …
PSMA) treatment in metastatic castration-resistant prostate cancer (PCa) in our institution …
Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.
228 Background: Lutetium-177 (177Lu)-PSMA-617 (LuPSMA) is a radiolabelled small
molecule that binds with high affinity to prostate specific membrane antigen (PSMA) …
molecule that binds with high affinity to prostate specific membrane antigen (PSMA) …
[HTML][HTML] Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate …
WP Fendler, S Reinhardt, H Ilhan, A Delker, G Böning… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177 Lu-PSMA-617 …
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177 Lu-PSMA-617 …
Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer–a narrative review
P Szponar, P Petrasz, K Brzeźniakiewicz-Janus… - Frontiers in …, 2023 - frontiersin.org
Introduction Radio-ligand targeted therapy is a new and promising concept of treatment
Castration resistant prostate cancer (CRPC). Only a few radio-pharmaceutics were …
Castration resistant prostate cancer (CRPC). Only a few radio-pharmaceutics were …
576MO Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration …
K Fizazi, K Herrmann, BJ Krause, K Rahbar… - Annals of …, 2021 - annalsofoncology.org
Background [177 Lu] Lu-PSMA-617 (177 Lu-PSMA-617) delivers β-particle radiation to
prostate-specific membrane antigen (PSMA) expressing cells and the surrounding …
prostate-specific membrane antigen (PSMA) expressing cells and the surrounding …